Commentary · 13 Jan 2025
Review articlePublished 24 Aug 2016
Regulatory Exclusivities or Non-patent exclusivities
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Pharmaceutical development is an expensive, time consuming and uncertain process that takes years to complete. Often, patent protection expires before a new drug is approved for marketing. As a result, most pharmaceutical companies in the United States and European Union (EU) depend on the exclusivity rights granted under the U.S. Federal Food, Drug and Cosmetic Act (FDCA), and the corresponding EU authorities to recoup their considerable investment in the drug development and approval process. Therefore, pharmaceutical companies must understand and employ the different forms of nonpatent exclusivity in both the U.S. and EU in order to succeed in the global marketplace.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Civil & Legal Sciences.
Editorial · 29 Nov 2024
The Global Struggle for Human Rights: Legal Frameworks and Their Impact
Perspective · 29 Nov 2024
Judicial Activism: The Role of Courts in Shaping Public Policy
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Civil & Legal Sciences
- SubjectEngineering
- SubjectSocial Sciences & Humanities
- BylineArticles whose byline prints “Eleti Shivanvitha”
